Biotech RadarJobs updated

COMPANY

Moderna

HQ: Cambridge, MA source · modernatx.com ↗ · New England

FDA-approved therapeutic company Clinical Phase 3

279 open jobs · last seen Oct 23, 2026 · 55 sources

Keywords: mRNA Influenza SARS-CoV-2 Respiratory Syncytial Virus Cytomegalovirus Infection COVID-19 Propionic Acidemia Seasonal Influenza Epstein-Barr Virus Infection Lyme Disease Cytomegalovirus Norovirus Acute Gastroenteritis Methylmalonic Acidemia Ebola-Bundibugyo Virus Disease Relapsed or Refractory Multiple Myeloma Melanoma Human Metapneuomovirus Herpes Zoster Human Metapneumovirus Multiple Sclerosis Acute Gastroenteritis Genital Herpes Epstein-Barr Virus Glycogen Storage Disease mRNA-1345 mRNA-1647 mRNA-3705 mRNA-1189 mRNA-3927 mRNA-1083 mRNA-1469 mRNA-2808 mRNA-0184 mRNA-1018-H5 mRNA-1982 mRNA-1195 mRNA-1403 mRNA-1273.712

Location: Cambridge, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

279Open jobs115Trials (company is sponsor)6FDA records (2 yrs)

Hiring

TitleLocation (from posting)Employer postedFirst seen
MSAT DS Engineer III & PackagingOxford - EnglandOct 23, 2026Oct 23, 2026
Process Technician - MechanicalMelbourne - AustraliaOct 23, 2026Oct 23, 2026
Process Technician - ElectricalMelbourne - AustraliaOct 23, 2026Oct 23, 2026
Sr. Research AssociateCambridge, MassachusettsOct 22, 2026Oct 22, 2026
Specialist, Quality ControlNorwood, MassachusettsOct 22, 2026Oct 23, 2026

See all 279 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

  1. Trial start Phase 4: A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations source ↗
  2. Board tracked Radar started tracking this company’s job board (279 open jobs at last check). source ↗
  3. Trial start Phase 2: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age source ↗
  4. Debt Debt: $2.6B (not counted as a raise), announced Aug 28, 2026. Source: SEC filing. source ↗
  5. Trial start Phase 1: A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults source ↗
  6. FDA FDA New drug/biologic (novel): Flusiva, Mflusiva (influenza vaccine, mrna) — BLA125869, Aug 5, 2026. Applicant at approval: ModernaTX, Inc. Accelerated approval. source ↗
  7. Trial start Phase 1: A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants source ↗
  8. Trial start Phase 2: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age) source ↗
  9. Trial start Phase 3: A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults source ↗
  10. Trial start Phase 1: A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age source ↗
  11. Trial start Phase 4: A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) source ↗
  12. Trial start Phase 1/Phase 2: A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma source ↗
  13. FDA FDA CBER noteworthy supplement: SPIKEVAX (covid-19 vaccine, mrna) — BLA125752/305, Aug 27, 2025. Applicant at approval: Moderna TX, Inc. source ↗
  14. FDA FDA CBER noteworthy supplement: MNEXSPIKE (covid-19 vaccine, mrna) — BLA125835/6, Aug 27, 2025. Applicant at approval: ModernaTX, Inc. source ↗
  15. Trial start Phase 3: A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age source ↗
  16. Trial start Phase 4: A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations source ↗
  17. FDA FDA CBER noteworthy supplement: SPIKEVAX (covid-19 vaccine) — BLA125752/276, Jul 9, 2025. Applicant at approval: ModernaTX, Inc. source ↗
  18. FDA FDA CBER noteworthy supplement: MRESVIA (respiratory syncytial virus vaccine) — BLA125796/37, Jun 12, 2025. Applicant at approval: ModernaTX, Inc. source ↗
  19. FDA FDA Original approval: mnexspike (covid-19 vaccine, mrna) — BLA125835, May 30, 2025. Applicant at approval: Moderna TX, Inc. source ↗
  20. Trial start Phase 2: A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years source ↗
  21. Trial start Phase 1: A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors source ↗
  22. Trial start Phase 3: Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age source ↗
  23. Trial start Phase 1: A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants source ↗
  24. Trial start Phase 4: A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age source ↗
  25. Trial start Phase 3: A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis source ↗

Showing 25 of 58 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 279

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
MSAT DS Engineer III & PackagingOxford - EnglandOct 23, 2026Oct 23, 2026Not stated
Process Technician - MechanicalMelbourne - AustraliaOct 23, 2026Oct 23, 2026Not stated
Process Technician - ElectricalMelbourne - AustraliaOct 23, 2026Oct 23, 2026Not stated
Sr. Research AssociateCambridge, MassachusettsOct 22, 2026Oct 22, 2026Not stated
Specialist, Quality ControlNorwood, MassachusettsOct 22, 2026Oct 23, 2026Not stated
Manufacturing Associate INorwood, MassachusettsOct 22, 2026Oct 23, 2026Not stated
Vice President, Therapeutics ImmunologyCambridge, MassachusettsOct 22, 2026Oct 23, 2026Not stated
Analyst, Quality Control, Chemistry & StabilityOxford - EnglandOct 21, 2026Oct 21, 2026Not stated
Analyst, Quality Control, Chemistry & StabilityOxford - EnglandOct 21, 2026Oct 21, 2026Not stated
Analyst, Quality Control, Chemistry & StabilityOxford - EnglandOct 21, 2026Oct 21, 2026Not stated
Analyst, Quality Control, Chemistry & StabilityOxford - EnglandOct 21, 2026Oct 21, 2026Not stated
Analyst, Quality Control, Chemistry & StabilityOxford - EnglandOct 21, 2026Oct 21, 2026Not stated
Sr. Engineer II, Process and Product Development - ClinicalNorwood, MassachusettsOct 21, 2026Oct 21, 2026Not stated
Sr. Manager, Biomarker OperationsCambridge, MassachusettsOct 21, 2026Oct 7, 2026Not stated
Associate Director, Clinical Operations – Therapeutics/OncologyCambridge, MassachusettsOct 20, 2026Oct 7, 2026Senior
Senior Scientist, Translational ImmunologyCambridge, MassachusettsOct 20, 2026Oct 20, 2026Not stated
Procurement & Contract ManagerWarsaw - PolandOct 20, 2026Oct 20, 2026Not stated
Intern, Global Safety Epidemiology, Infectious Rare DiseaseCambridge, MassachusettsOct 20, 2026Oct 21, 2026Not stated
Co-Op, Immuno-Oncology ResearchCambridge, MassachusettsOct 19, 2026Oct 7, 2026Entry
Cost Accounting ManagerNorwood, MassachusettsOct 19, 2026Oct 7, 2026Mid
Cluster Lead, Pharmacovigilance, LATAMCambridge, MassachusettsOct 19, 2026Oct 17, 2026Not stated
Sr. Director, Regional Sales, Central - IntismeranRemote - USOct 19, 2026Oct 19, 2026Not stated
Sr. Director, Regional Sales, Northeast - IntismeranRemote - USOct 19, 2026Oct 19, 2026Not stated
Sr. Director, Regional Sales, South - IntismeranRemote - USOct 19, 2026Oct 19, 2026Not stated
Sr. Director, Regional Sales, West - IntismeranRemote - USOct 19, 2026Oct 19, 2026Not stated
Sr. Research Associate, Analytical Technical OperationsNorwood, MassachusettsOct 19, 2026Oct 19, 2026Not stated
Sr. Specialist, SAP Center of Excellence, MESHWarsaw - PolandOct 19, 2026Oct 19, 2026Not stated
Principal Technical Program ManagerSeattle, WashingtonOct 19, 2026Oct 20, 2026Not stated
Sr. Technical Program Manager, AI SecurityCambridge, MassachusettsOct 16, 2026Oct 7, 2026Senior
Sr. Technical Program Manager, Cybersecurity RemediationCambridge, MassachusettsOct 16, 2026Oct 7, 2026Senior
Sr. Engineer I, Robotics ApplicationsNorwood, MassachusettsOct 16, 2026Oct 17, 2026Not stated
Manager, Logistics OperationsCambridge, MassachusettsOct 16, 2026Oct 17, 2026Not stated
ABAP BTP EngineerCambridge, MassachusettsOct 16, 2026Oct 17, 2026Not stated
Oracle EPM Cloud Administrator, Digital FP&ACambridge, MassachusettsOct 16, 2026Oct 17, 2026Not stated
Sr. Director, New Product Planning, OncologyCambridge, MassachusettsOct 16, 2026Oct 17, 2026Not stated
Sr. Director, New Product Planning, AutoimmuneCambridge, MassachusettsOct 16, 2026Oct 17, 2026Not stated
Associate Director, Global Regulatory Science, CMCLondon - EnglandOct 15, 2026Oct 7, 2026Senior
Co-Op, Business Operations & Operational ExcellenceNorwood, MassachusettsOct 15, 2026Oct 16, 2026Not stated
Co-Op, Supply Chain & LogisticsNorwood, MassachusettsOct 15, 2026Oct 16, 2026Not stated
Co-Op, Quality Assurance & ComplianceNorwood, MassachusettsOct 15, 2026Oct 16, 2026Not stated
Co-Op, Biopharmaceutical Manufacturing OperationsNorwood, MassachusettsOct 15, 2026Oct 16, 2026Not stated
Co-Op, Process Engineering, CQV & Manufacturing EngineeringNorwood, MassachusettsOct 15, 2026Oct 16, 2026Not stated
Co-Op, Automation, Digital Manufacturing & ControlsNorwood, MassachusettsOct 15, 2026Oct 16, 2026Not stated
Co-Op, Facilities, Plant & Project EngineeringNorwood, MassachusettsOct 15, 2026Oct 16, 2026Not stated
Associate II, Quality Control, StabilityNorwood, MassachusettsOct 15, 2026Oct 16, 2026Not stated
Sr. Specialist, Quality Control, Reference MaterialNorwood, MassachusettsOct 15, 2026Oct 16, 2026Not stated
Head of Analytical DevelopmentNorwood, MassachusettsOct 15, 2026Oct 16, 2026Not stated
Specialist, Quality ControlMadrid - SpainOct 15, 2026Oct 16, 2026Not stated
Sr. Specialist, Quality ControlMadrid - SpainOct 15, 2026Oct 16, 2026Not stated
Associate Director, Global Regulatory Science, CMCNorwood, MassachusettsOct 14, 2026Oct 7, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

All 279 jobs →

Funding

Debt: $2.6B. Last 2 years.

Clinical trials (lead sponsor) Showing 50 of 115

RecordTitlePhaseStatusStartPrimary completion
NCT06508320A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)Phase 2CompletedJul 15, 2024Sep 25, 2025 (actual)
NCT07863635A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsPhase 4Not yet recruitingOct 9, 2026Jan 9, 2027 (estimated)
NCT05127434A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of AgePhase 2/Phase 3CompletedNov 17, 2021Jul 28, 2025 (actual)
NCT07266558A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)Phase 4Active, not recruitingNov 26, 2025Jun 16, 2027 (estimated)
NCT07737717A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult ParticipantsPhase 1Active, not recruitingJul 31, 2026Sep 30, 2027 (estimated)
NCT07116616A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple MyelomaPhase 1/Phase 2RecruitingSep 30, 2025Jun 17, 2030 (estimated)
NCT06602024A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of AgePhase 3CompletedSep 16, 2024Aug 21, 2025 (actual)
NCT06655870A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy ParticipantsPhase 1RecruitingOct 31, 2024Dec 16, 2026 (estimated)
NCT07808697A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of AgePhase 2Not yet recruitingSep 1, 2026Aug 30, 2029 (estimated)
NCT03897881An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)Phase 2Active, not recruitingJul 18, 2019Nov 21, 2032 (estimated)
NCT03313778Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid TumorsPhase 1Active, not recruitingAug 14, 2017Nov 21, 2027 (estimated)
NCT06067230A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk AdultsPhase 3CompletedOct 6, 2023Jul 24, 2026 (actual)
NCT07764237A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy AdultsPhase 1RecruitingAug 11, 2026Jul 20, 2027 (estimated)
NCT06097299A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial VirusPhase 2CompletedOct 24, 2023Jun 27, 2025 (actual)
NCT07496450A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsPhase 3Active, not recruitingMar 23, 2026Jan 28, 2027 (estimated)
NCT05831111A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy ParticipantsPhase 1Active, not recruitingApr 5, 2023Oct 13, 2026 (estimated)
NCT06880549A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid TumorsPhase 1RecruitingMar 25, 2025Aug 3, 2027 (estimated)
NCT05683457A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.Phase 2Active, not recruitingApr 5, 2023Mar 6, 2027 (estimated)
NCT05701800A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of AgePhase 1TerminatedJan 23, 2023Dec 31, 2025 (actual)
NCT07561294A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)Phase 2Active, not recruitingApr 29, 2026Nov 9, 2028 (estimated)
NCT05975099A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of AgePhase 1/Phase 2CompletedJul 26, 2023May 30, 2025 (actual)
NCT05533697Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid TumorsPhase 1/Phase 2RecruitingSep 1, 2022Feb 18, 2032 (estimated)
NCT07089706A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing FormulationsPhase 4CompletedJul 21, 2025Jun 16, 2026 (actual)
NCT05743881A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 MonthsPhase 1Active, not recruitingFeb 15, 2023Aug 31, 2029 (estimated)
NCT06735248A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 YearsPhase 2RecruitingApr 16, 2025Jan 8, 2029 (estimated)
NCT06143046A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated MothersPhase 2CompletedNov 15, 2023May 25, 2026 (actual)
NCT05575492A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of AgePhase 1/Phase 2CompletedNov 7, 2022May 12, 2026 (actual)
NCT06592794A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute GastroenteritisPhase 3Active, not recruitingSep 24, 2024Feb 15, 2027 (estimated)
NCT06033261A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital HerpesPhase 1/Phase 2CompletedSep 6, 2023Apr 25, 2025 (actual)
NCT04899310A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic AcidemiaPhase 1/Phase 2TerminatedAug 6, 2021Apr 1, 2026 (actual)
NCT05164094A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and AdultsPhase 1/Phase 2Active, not recruitingDec 28, 2021Oct 5, 2026 (estimated)
NCT04232280Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy AdultsPhase 2CompletedJan 9, 2020Jan 4, 2023 (actual)
NCT07117487A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of AgePhase 3CompletedAug 5, 2025Mar 27, 2026 (actual)
NCT05815498A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19Phase 3CompletedMar 28, 2023Apr 12, 2025 (actual)
NCT06333704Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGENot listedActive, not recruitingMar 10, 2023Mar 29, 2029 (estimated)
NCT05992935Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of AgePhase 1/Phase 2Active, not recruitingAug 25, 2023Sep 22, 2026 (estimated)
NCT06585241A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsPhase 4RecruitingSep 9, 2024Dec 31, 2026 (estimated)
NCT07478952A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of AgePhase 1RecruitingMar 17, 2026May 15, 2027 (estimated)
NCT05130437A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 StudyPhase 1/Phase 2RecruitingNov 9, 2021Dec 4, 2029 (estimated)
NCT05397223A Study of Modified mRNA Vaccines in Healthy AdultsPhase 1CompletedMay 24, 2022Feb 27, 2026 (actual)
NCT05769621A Retrospective Study to Characterize Participants With Propionic AcidemiaNot listedRecruitingJun 16, 2023Sep 30, 2026 (estimated)
NCT06634797A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of AgePhase 4CompletedOct 8, 2024Jan 20, 2025 (actual)
NCT04975893A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 VaccinePhase 2CompletedJun 18, 2021Jan 19, 2026 (actual)
NCT04159103Open-Label Study of mRNA-3927 in Participants With Propionic AcidemiaPhase 1/Phase 2RecruitingApr 15, 2021Aug 31, 2027 (estimated)
NCT05330975A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of AgePhase 3CompletedApr 1, 2022Nov 8, 2024 (actual)
NCT05295433An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705Phase 1/Phase 2RecruitingMar 8, 2022Apr 2, 2034 (estimated)
NCT05827926A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy AdultsPhase 1/Phase 2CompletedApr 14, 2023Dec 3, 2024 (actual)
NCT05085366A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of AgePhase 3TerminatedOct 26, 2021Nov 4, 2025 (actual)
NCT05095727A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)Phase 1/Phase 2Active, not recruitingJun 1, 2022Nov 30, 2026 (estimated)
NCT06694389Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of AgePhase 3CompletedNov 18, 2024Nov 17, 2025 (actual)

FDA records (last 2 years)

Connect

See your connections at Moderna on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback